3. DRUGS AND COSMETICS ACT 1940 AND RULES 1945 AND NEW AMENDMENTS

Written and reviewed by Dr. Saint Paul | Pharm.D Graduate from JNTUK | Pharmacy Educator and D.Pharmacy Academic Content Creator

Continuous use of cosmetics in luxury items may prove harmful as they may contain harmful ingredients. Therefore, there is a need to control cosmetics. This Act verifies that drugs and cosmetics should be manufactured, distributed, and sold only by qualified persons having a licence for this purpose. Central and State Drugs Control authorities are recognised to control these actions. The main aim of the Act is to regulate the import, manufacture, distribution, and sale of drugs and cosmetics.

  1. Preventing substandard drugs and maintaining high medical standards
  2. Controlling import, manufacture, distribution, and sale of drugs and cosmetics by licensing
  3. Ensuring manufacture, distribution, and sale is done by qualified persons only
  4. Controlling manufacture and sale of Ayurvedic, Siddha, and Unani drugs
  5. Establishing Drugs Technical Advisory Board (DTAB) and Drugs Consultative Committees (DCC)

Any article intended to be rubbed, poured, sprinkled, or sprayed on, or introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance, including any article intended for use as a component of cosmetic.

  • All medicines for internal or external use of human beings or animals
  • Substances intended for diagnosis, treatment, mitigation, or prevention of disease
  • Substances intended to affect body structure or function
  • Substances intended for use as components of a drug (including empty gelatin capsules)
  • Devices intended for diagnosis, treatment, mitigation, or prevention of disease
  • If damage is concealed by colouring, coating, powdering, or polishing
  • If not labelled in prescribed manner
  • If label or container bears any false or misleading claim
  • Contains filthy, putrid, or decomposed substance
  • Prepared, packed, or stored under insanitary conditions
  • Container composed of poisonous or deleterious substance
  • Contains harmful or toxic substance
  • Any substance mixed to reduce quality or strength
  • Imported under a name belonging to another drug
  • Imitation of or substitute for another drug
  • Label bears name of fictitious or non-existent manufacturer
  • Substituted wholly or partly by another drug or substance
  • Purports to be product of a manufacturer of whom it is not truly a product
  • First Schedule: Books under Ayurvedic, Siddha, Unani, and Tibb systems
  • Second Schedule: Standards for imported and manufactured drugs
  • Schedule A: Proforma for licence applications, issue, renewal
  • Schedule B: Rates of fee for test or analysis
  • Schedule C & C₁: Biological and special products (sera, vaccines, hormones, toxins, antitoxins)
  • Schedule D: Drugs exempted from import provisions
  • Schedule F: Blood bank requirements; vaccine production standards
  • Schedule F₂: Standards for surgical dressings
  • Schedule FF: Standards for ophthalmic preparations
  • Schedule G: Drugs requiring medical supervision (“It is dangerous to take this preparation except under medical supervision”)
  • Schedule H: Prescription drugs (551 drugs; label with “Rx”)
  • Schedule H₁: Sensitive antibiotics, habit-forming medications (red Rx label)
  • Schedule J: Diseases which a drug may not prevent or cure
  • Schedule K: Drugs exempted from certain manufacture provisions (household remedies, etc.)
  • Schedule M: Good Manufacturing Practices (GMP) requirements
  • Schedule N: Minimum equipment for efficient running of a pharmacy
  • Schedule P: Life periods of drugs (expiry dates)
  • Schedule P₁: Pack sizes of drugs
  • Schedule Q: Dyes, colours, and pigments permitted in cosmetics
  • Schedule R: Standards for condoms and medical devices
  • Schedule S: Standards for cosmetics
  • Schedule T: Factory premises for Ayurvedic, Siddha, Unani drugs
  • Schedule U: Manufacturing and analytical records
  • Schedule W: Drugs to be marketed under generic names only
  • Schedule X: Habit-forming and narcotic drugs (addictive potential; special storage)
  • Schedule Y: Requirements and guidelines for clinical trials of new drugs
  • Non-standard quality drugs or cosmetics
  • Misbranded, spurious, or adulterated drugs
  • Drugs requiring licence for import (without licence)
  • Patent/proprietary medicines without true formula on label
  • Drugs claiming to cure diseases specified in Schedule J
  • Cosmetics containing unsafe or harmful ingredients
  • Drugs prohibited in country of origin
  • Drugs not labelled and packed in prescribed manner
  • Expired biological products (Schedule C and C₁)
  • New drugs without express permission of licensing authority
  • Schedule C and C₁ drugs (excluding Schedule X)
  • Schedule X drugs
  • Small quantities for examination, test, or analysis
  • Drugs for personal use prescribed by RMP
  • New drugs
  • Schedule C and C₁ drugs (biological and special products)
  • Schedule X drugs (habit-forming/narcotic drugs)
  • Schedules C, C₁ and X drugs
  • Drugs for examination, test, or analysis
  • Patent and proprietary medicines
  • New drugs
  • Loan licence (manufacturing at another person’s premises)
  • Repacking licence
OffencePenalty
Manufacture of adulterated/spurious drug causing death or serious hurtImprisonment 5 years + fine not less than ₹10,000
Manufacture without licence or adulterated drug (no death/serious hurt)Imprisonment 1-3 years + fine not less than ₹5,000
Manufacture in contravention of any other provisionImprisonment 1-2 years + fine
Failure to keep records or disclose required informationImprisonment up to 1 year and/or fine up to ₹1,000
  • Wholesale: From fixed premises or motor vehicles; separate licences for Schedule C/C₁ and other drugs
  • Retail – Chemists & Druggists: Under supervision of registered pharmacist (no compounding)
  • Retail – Pharmacies: Under supervision of registered pharmacist (compounding allowed)
  • Drug Stores: No registered pharmacist; only household remedies
  • Restricted Licences: For vendors in sparsely populated areas, travelling agents
  • Retail only on RMP prescription
  • Prescription not dispensed more than once (unless specified)
  • No substitution allowed
  • Schedule X prescriptions in duplicate; retained for 2 years
  • Separate bound registers maintained
  • Schedule X drugs stored in locked cabinet/drawer
  • Dispensing department area: minimum 6 m² (plus 2 m² per additional pharmacist)
  • Minimum height: 2.5 m
  • Poison cupboard marked “POISON” in red letters
  • Apparatus: dispensing balance (30 mg sensitivity), counter balance (3 kg, 1 g sensitivity), beakers, prescription bottles, mortars & pestles, pipettes, thermometers, water still, weights (1 mg-100 g), etc.
  • Books: Indian Pharmacopoeia (current), National Formulary of India, Drugs and Cosmetics Act & Rules, Pharmacy Act, Narcotic Drugs and Psychotropic Substances Act
  • Chairman: Director-General of Health Services
  • Members: Drugs Controller of India, Director CDL, Director CRI Kasauli, President PCI, President MCI, and others
  • Functions: Advises Central/State Governments on technical matters; recommends modifications/amendments
  • Established in Calcutta
  • Analyses drug/cosmetic samples sent by courts or customs collectors
  • Sera, vaccines, etc., sent to Central Research Institute, Kasauli
  • Veterinary products sent to Indian Veterinary Institute, Izzatnagar
  • 2 Central Government nominees + 1 nominee from each State Government
  • Advises on securing uniformity in administration of the Act
  • Appointed by Central or State Governments
  • Qualifications: Degree in pharmacy/pharmaceutical sciences/medicine with clinical pharmacology/microbiology
  • Duties: Inspect licenced premises, obtain samples, investigate complaints, institute legal proceedings, seize stocks if necessary
  • Inspect premises at least twice a year
  • Permanent licences for manufacturing introduced
  • Licence remains valid if retention fee paid every 5 years
  • Late fee of 2% per month for delayed payment (up to 6 months)
  • Non-payment beyond 6 months results in deemed cancellation
  • Renewal provisions omitted for many forms
OffencePenalty
Sale of drugs causing death or serious hurtImprisonment 5 years to life + fine not less than ₹10,000
Sale of spurious drugs1-3 years + fine up to ₹5,000 (first); 2-6 years + fine ₹10,000 (subsequent)
Sale in contravention of other provisions1-2 years imprisonment + fine
False warranty to purchaserImprisonment 1 year + fine up to ₹5,000 (first); up to 2 years (subsequent)
Share your love

Leave a Reply

Your email address will not be published. Required fields are marked *